They should not be directly involved in deciding on the final set of recommendations. An individual can serve in only one capacity. The participation of liaison members can also facilitate the quick dissemination of the recommendations back to the membership of the professional organization when settled. This helps to ensure support for and quick and smooth implementation of the new recommendations. It is recommended that the committee be multidisciplinary and represent a broad range of skills and expertise through the selection of technically sound and experienced individuals as members. At a Selleckchem PD-1/PD-L1 inhibitor 2 minimum and when feasible (i.e. depending on the size and capacity of country), it is
recommended for countries to consider including experts as core members from the following disciplines/areas: clinical
medicine (paediatrics and adolescent medicine, adult medicine, geriatrics), epidemiologists, infectious diseases specialists, microbiologists, public health, immunology, vaccinology, immunization programme, and health systems and delivery. Consideration should also be given to appointing members with expertise in clinical research (clinical trials design) and health economics. Such expertise, however, Navitoclax clinical trial may be limited in some settings and individual countries could consider providing ability to interpret cost-effectiveness studies via the secretariat and/or expertise beyond that of the core group. The collective expertise should obviously be adjusted to the specific terms of reference for the group. Other considerations in terms of membership include: gender distribution, geographic diversity, representation of special population groups, and the need or not to ensure representation of the public. This latter member might be a consumer representative who could bring the consumer’s perspective the or social and community aspects of immunization programmes. If public representation is desired, decisions need to be made
on how this could be done (i.e. through a seat on the core membership or rather through ex officio or liaison members) and how to identify a suitable representative. Given the substantial financial implications that recommendations may have for the public and private sectors, as well as for vaccine manufacturers, members should be free of conflicts of interest and enjoy satisfactory credibility. Members with declared interests compatible with serving on the committee will be asked to recuse themselves from participating in the discussion and decision making of the issues relating to that interest. A member who is in any doubt as to whether they have a conflict of interest that should be declared, or whether they should take part in the proceedings, should ask the Secretariat and Chairperson for guidance.